Novel glutamine antagonist prodrugs to be developed as anticancer therapies

(Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague)) An international science team at IOCB Prague and Johns Hopkins University (Baltimore, USA) has prepared and tested new substances for cancer treatment that are effective through stopping the metabolism of glutamine. The team's promising results attracted investors supporting the development of these new drugs in the amount of $40.5 million. Further preclinical development and clinical testing will be led by spin-off company Dracen Pharmaceuticals.